A recent study found 32 new sites on the human genome where variations in a woman’s DNA could alter her risk level, both increase and decrease, of getting breast cancer.
The multi-center trial is comprised of 2 phases, with phase I determining the maximum tolerated dose of palbociclib and phase II determining the clinical benefit rate of treatment with anastrozole, palbociclib, trastuzumab, and pertuzumab.
As prospective clinical trials continue to accrue data, the researchers indicated that this data may help clinicians in decision-making regarding adjuvant systemic therapy for patients with small HR-positive, ERBB2-positive breast cancers.
This study observed a positive association between Indigenous American genetic ancestry and HER2-positive breast cancer, suggesting that the high incidence of HER2-positive subtypes in Latinas may be due to population and subtype-specific genetic risk variants.
The FDA approved tucatinib in combination with chemotherapy for the treatment of adult patients with advanced forms of HER2-positive breast cancer.
Immutep reported positive data from the randomized phase IIb AIPAC clinical trial of eftilagimod alpha and paclitaxel in HER2-negative, HR-positive metastatic breast cancer (MBC).
The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting.
The FDA accepted a biologics license application for the fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, administered by subcutaneous injection in combination with IV chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer.
The breast cancer expert, in an interview with CancerNetwork®, discussed advances in the field of breast cancer and what we can expect to see in the pipeline moving forward.
The FDA granted a priority review to a new drug application submitted by Seattle Genetics, Inc. for tucatinib to treat patients with HER2-positive breast cancer.